嘉应制药及董事长李能等因信披违规收证监会罚单

Group 1 - The core issue involves Guangdong Jiaying Pharmaceutical Co., Ltd. facing administrative penalties from the China Securities Regulatory Commission for failing to disclose related party transactions [1] - The company’s subsidiary, Hunan Jiaying, provided short-term loans to a related party, Hunan Yaojuneng Pharmaceutical Co., Ltd., controlled by the chairman, amounting to 219.99 million yuan, which is 28.83% of the company's latest audited net assets [1] - The related party transactions were not properly reviewed or disclosed until the 2024 annual report, violating relevant securities laws [1] Group 2 - The Guangdong Securities Regulatory Bureau plans to impose a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical [1] - Chairman Li Neng is to receive a warning and a fine of 1.6 million yuan, while other executives, including General Manager You Yongping and former CFO Shi Junping, will also face fines [1]